These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 23821350)

  • 1. Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration.
    St Pierre TG; El-Beshlawy A; Elalfy M; Al Jefri A; Al Zir K; Daar S; Habr D; Kriemler-Krahn U; Taher A
    Magn Reson Med; 2014 Jun; 71(6):2215-23. PubMed ID: 23821350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
    Porter JB; Elalfy MS; Taher AT; Aydinok Y; Chan LL; Lee SH; Sutcharitchan P; Habr D; Martin N; El-Beshlawy A
    Ann Hematol; 2013 Jan; 92(2):211-9. PubMed ID: 23086508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.
    Porter JB; Elalfy M; Taher A; Aydinok Y; Lee SH; Sutcharitchan P; El-Ali A; Han J; El-Beshlawy A
    Eur J Haematol; 2017 Mar; 98(3):280-288. PubMed ID: 27859648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).
    Ho PJ; Tay L; Teo J; Marlton P; Grigg A; St Pierre T; Brown G; Badcock CA; Traficante R; Gervasio OL; Bowden DK
    Eur J Haematol; 2017 Feb; 98(2):97-105. PubMed ID: 27537786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan.
    Garbowski MW; Carpenter JP; Smith G; Roughton M; Alam MH; He T; Pennell DJ; Porter JB
    J Cardiovasc Magn Reson; 2014 Jun; 16(1):40. PubMed ID: 24915987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.
    Inati A; Kahale M; Sbeiti N; Cappellini MD; Taher AT; Koussa S; Nasr TA; Musallam KM; Abbas HA; Porter JB
    Pediatr Blood Cancer; 2017 Jan; 64(1):188-196. PubMed ID: 27576370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.
    Deugnier Y; Turlin B; Ropert M; Cappellini MD; Porter JB; Giannone V; Zhang Y; Griffel L; Brissot P
    Gastroenterology; 2011 Oct; 141(4):1202-11, 1211.e1-3. PubMed ID: 21741344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
    Taher A; El-Beshlawy A; Elalfy MS; Al Zir K; Daar S; Habr D; Kriemler-Krahn U; Hmissi A; Al Jefri A
    Eur J Haematol; 2009 Jun; 82(6):458-65. PubMed ID: 19187278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience.
    Karakas Z; Yilmaz Y; Bayramoglu Z; Karaman S; Aydogdu S; Karagenc AO; Tugcu D; Dursun M
    Radiol Med; 2018 Aug; 123(8):572-576. PubMed ID: 29663188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox.
    Taher AT; Porter JB; Viprakasit V; Kattamis A; Chuncharunee S; Sutcharitchan P; Siritanaratkul N; Origa R; Karakas Z; Habr D; Zhu Z; Cappellini MD
    Eur J Haematol; 2014 Jun; 92(6):521-6. PubMed ID: 24460655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of MRI technique on clinical decision-making in patients with liver iron overload: comparison of FerriScan- versus R2*-derived liver iron concentration.
    Sussman MS; Ward R; Kuo KHM; Tomlinson G; Jhaveri KS
    Eur Radiol; 2020 Apr; 30(4):1959-1968. PubMed ID: 31953658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: results from the ESCALATOR study.
    Taher A; Elalfy MS; Al Zir K; Daar S; Al Jefri A; Habr D; Kriemler-Krahn U; Roubert B; El-Beshlawy A
    Eur J Haematol; 2011 Oct; 87(4):349-54. PubMed ID: 21668501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Evaluation of an R2* Method for Assessing Liver Iron Concentration (LIC) Against FerriScan: Derivation of the Calibration Curve and Characterization of the Nature and Source of Uncertainty in the Relationship.
    Jhaveri KS; Kannengiesser SAR; Ward R; Kuo K; Sussman MS
    J Magn Reson Imaging; 2019 May; 49(5):1467-1474. PubMed ID: 30291649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study.
    Taher AT; Porter JB; Viprakasit V; Kattamis A; Chuncharunee S; Sutcharitchan P; Siritanaratkul N; Galanello R; Karakas Z; Lawniczek T; Habr D; Ros J; Zhu Z; Cappellini MD
    Ann Hematol; 2013 Nov; 92(11):1485-93. PubMed ID: 23775581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.
    Pathare A; Taher A; Daar S
    Ann Hematol; 2010 Apr; 89(4):405-9. PubMed ID: 19798501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spin density projection-assisted R2 magnetic resonance imaging of the liver in the management of body iron stores in patients receiving multiple red blood cell transfusions: an audit and retrospective study in South Australia.
    Brown GC; Patton WN; Tapp HE; Taylor DJ; St Pierre TG
    Intern Med J; 2012 Sep; 42(9):990-6. PubMed ID: 22647084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Inline R2* MRI versus FerriScan for liver iron quantification in patients on chelation therapy for iron overload: preliminary results.
    Healy GM; Kannengiesser SAR; Espin-Garcia O; Ward R; Kuo KHM; Jhaveri KS
    Eur Radiol; 2021 Dec; 31(12):9296-9305. PubMed ID: 34041571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.
    Taher AT; Porter J; Viprakasit V; Kattamis A; Chuncharunee S; Sutcharitchan P; Siritanaratkul N; Galanello R; Karakas Z; Lawniczek T; Ros J; Zhang Y; Habr D; Cappellini MD
    Blood; 2012 Aug; 120(5):970-7. PubMed ID: 22589472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.
    Tsouana E; Kaya B; Gadong N; Hemmaway C; Newell H; Simmons A; Whitmarsh S; Telfer P
    Eur J Haematol; 2015 Apr; 94(4):336-42. PubMed ID: 25138173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.